0.7965
전일 마감가:
$0.7368
열려 있는:
$0.7122
하루 거래량:
180.19K
Relative Volume:
1.67
시가총액:
$23.06M
수익:
$26.55M
순이익/손실:
$-91.72M
주가수익비율:
-0.2222
EPS:
-3.584
순현금흐름:
$-13.25M
1주 성능:
+2.96%
1개월 성능:
-1.46%
6개월 성능:
-38.73%
1년 성능:
-54.22%
Celularity Inc Stock (CELU) Company Profile
명칭
Celularity Inc
전화
(908) 768-2170
주소
170 PARK AVE, FLORHAM PARK
Compare CELU vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
CELU
Celularity Inc
|
0.7965 | 22.29M | 26.55M | -91.72M | -13.25M | -3.584 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-01-30 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2022-12-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-06-22 | 개시 | H.C. Wainwright | Buy |
| 2022-04-06 | 다운그레이드 | Truist | Buy → Hold |
| 2022-01-28 | 개시 | Oppenheimer | Outperform |
| 2021-11-24 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Celularity Inc 주식(CELU)의 최신 뉴스
Celularity Inc. Warrant (CELUW) Holds at $0.01 Amid Minimal Volatility – Key Levels in FocusPCR Moving Average - newsline.com
Celularity Inc. 8-K Filing June 2026: Nasdaq Listing, Company Details, and Securities Information - Minichart
Celularity Faces Nasdaq Listing Compliance Risk After Notice - TipRanks
Celularity receives Nasdaq notice for non-compliance with $35 million market value rule - Investing.com
Celularity Received Notice of Noncompliance - TradingView
[8-K] Celularity Inc Reports Material Event - Stock Titan
Celularity (CELU) Slips 6% as Stock Approaches Key Support at $0.69Price Gap Fill - newsline.com
Celularity Inc. (CELU) Slips 7.4% as Selling Pressure Continues Near Key SupportLow Volatility Picks - newsline.com
CELU - Finviz
Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies - The Manila Times
New Florida law lets doctors use placental cell therapy before FDA approval - Stock Titan
Celularity names Rick Gonzalez as chief commercial officer - Investing.com UK
Celularity: Actions Are Intended to Streamline Business and Concentrate Resources >CELU - Moomoo
Celularity refocuses on cell therapy after biomaterials sale - Investing.com
Celularity Appoints Rick Gonzalez as Chief Commercial Officer - TipRanks
Celularity names Rick Gonzalez as Chief Commercial Officer - TradingView
New Celularity (NASDAQ: CELU) CCO to drive cenplacel-L and Lifebank growth - Stock Titan
Celularity refocuses on cell therapy after biomaterials sale By Investing.com - Investing.com UK
Celularity Releases CEO Letter to Shareholders - The Manila Times
Celularity outlines placenta cell therapy push to extend health span - Stock Titan
Celularity Inc. Appoints Rick Gonzalez as Chief Commercial Officer - geneonline.com
Celularity names Rick Gonzalez as chief commercial officer By Investing.com - Investing.com Australia
Celularity: Taken Important Steps to Sharpen Strategic Focus, Strengthen Fincl Position and Enable Celularity to Pursue the Opportunities Most Closely Aligned With Founding Vision - Moomoo
Celularity Inc. Appoints Rick Gonzalez as Chief Commercial Officer, Effective May 29, 2026 - marketscreener.com
Celularity Receives Nasdaq Notice Regarding Form 10-Q - marketscreener.com
Celularity face Nasdaq listing rule breach after missing Q1 10-Q SEC filing - MSN
Celularity gets Nasdaq notice for delayed Q1 2026 Form 10-Q filing, must submit compliance plan by July 28. - Pluang
Celularity Inc. Notified of Non-Compliance with Nasdaq Listing Rule Due to Delayed 10-Q Filing - Quiver Quantitative
Nasdaq flags Celularity for missing Q1 2026 10-Q filing - Stock Titan
Celularity Enters Settlement, Restructuring Financing Obligations - TipRanks
Celularityenters settlement agreement with Helena on May 21, 2026 - marketscreener.com
Celularity Settles With Helena; $500,000 Upfront, 5x$100,000 Payments and $2.5M Note Rights - TradingView
Celularity (NASDAQ: CELU) restructures Helena preferred stock deal with cash and note rights - Stock Titan
Celularity Inc. (CELU) Surges 8% to $0.99 as Stock Tests Key ResistanceEarly Entry Signals - The Legal Advocate
Celularity (CELU) Edges Higher: Navigating Key Resistance at $0.97PCR Divergence - thelegaladvocate.com
Why Is Celularity Inc. (GXGX) Stock Up Today? - Meyka
Why Is Celularity Inc. (GXGXW) Stock Down Today? - Meyka
Celularity Delays Quarterly SEC Filing - TipRanks
Celularity (NASDAQ: CELU) notifies SEC of delayed Q1 2026 10-Q - Stock Titan
NexGel Q1 2026 Earnings Call Transcript - MarketBeat
TradingKey - TradingKey
Sequence execs join NEXGEL (NASDAQ: NXGL) board after $5.5M note deal - Stock Titan
Is Celularity (CELU) a value trap or a value play? (Recovers) 2026-05-08Certified Trade Ideas - Newser
The hidden strength in Celularity (CELU) most investors miss (Underperforming) 2026-05-07Viral Trades - Newser
Celularity regains Nasdaq compliance after delayed filing - MSN
After $5.5M deal backing, Sequence executives take 2 NEXGEL board seats - Stock Titan
NEXGEL Appoints Brian Kieser and Kevin Harris from New - GlobeNewswire
NEXGEL Appoints Ian Blackman CFO Amid Celularity Deal - MyChesCo
Celularity Inc. 2025 Annual 10-K Report: Financials, Debt, Equity, and Major Agreements Overview - Minichart
Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation - Investing News Network
Stocks to watch on Friday after hours: CTLP, CELU, ULH (CTLP:NASDAQ) - Seeking Alpha
Celularity Inc (CELU) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Celularity Inc 주식 (CELU) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Haines John R | Senior Exec Vice President |
Apr 13 '26 |
Option Exercise |
0.00 |
1,641 |
0 |
30,762 |
| Hariri Robert J | Chief Executive Officer |
Apr 13 '26 |
Option Exercise |
0.00 |
3,281 |
0 |
2,854,735 |
자본화:
|
볼륨(24시간):